Nasogastric tube, a warning sign for high-flow nasal cannula failure in infants with bronchiolitis

Milena Siciliano Nascimento¹, Danielle E. R. Quinto, Gisele C. Z. Oliveira, Celso M. Rebello & Cristiane do Prado

High-flow nasal cannula (HFNC) therapy is routinely used in the treatment of infants with bronchiolitis. This study sought to identify markers associated with failure of HFNC therapy that serve as warnings for early staging of other ventilatory support products. A retrospective study of infants with a diagnosis of bronchiolitis, receiving HFNC and admitted to the pediatric intensive care unit from January 2016 to June 2017, was conducted. The subjects were divided into two study groups according to the success or failure of HFNC therapy. Risk factors were assessed using the following variables: age, time between hospital admission and start of HFNC, equipment model, and the need for a nasogastric tube. Eighty-one infants were studied, and 18 (21.7%) of them exhibited therapy failure. The results of the logistic models showed that the chances of failure for patients requiring a nasogastric tube during HFNC use were more likely than those for patients with oral nutrition (OR = 8.17; 95% CI 2.30–28.99; p = 0.001). The HFNC failure was not associated with the device used (OR = 1.56; 95% CI 0.54–4.52; p = 0.41), time between hospital admission and HFNC installation (OR = 1.01; 95% CI 0.98–1.03; p = 0.73), or age (OR = 0.98; 95% CI 0.82–1.17; p = 0.82). Among late outcomes evaluated, the patients with therapy failure had longer total durations of O₂ use (<0.001) and longer hospital stays (<0.001). The need to use a nasogastric tube during HFNC use was associated with HFNC therapy failure and can be considered as a marker of severity in children with bronchiolitis.

Treatment of bronchiolitis is based on symptoms and includes oxygen therapy, nutrition and hydration. The type of ventilatory support selected is based on increasing degrees of respiratory failure, namely, conventional oxygen therapy, high-flow nasal cannula (HFNC) use, noninvasive ventilation (NIV) with continuous positive airway pressure (CPAP) and, finally, invasive mechanical ventilation (IMV). HFNC therapy has emerged as a novel method to deliver warm, humidified air flow to provide noninvasive respiratory support with a titratable oxygen fraction that can generate a positive distending pressure with increased functional residual capacity and reduced breathing effort. This procedure is easier to use, better tolerated, and more comfortable for the patient when compared with nasal CPAP.

The use of HFNC therapy has been associated with improved washout of the nasopharyngeal dead space, better mucociliary clearance of the lung, and a more reliable oxygen supply compared with other oxygen delivery systems. HFNC has also been shown to reduce intubation rates and to improve oxygen saturation levels and is associated with decreases in EₐCO₂ (end-tidal carbon dioxide) and the respiratory rate (RR) in children with bronchiolitis in Intensive Care Units (ICUs). In the literature, some authors have studied physiological variables such as heart rate (HR), RR, inspired fraction of oxygen (FiO₂), and oxygen saturation (SpO₂) to determine HFNC therapy failure. Although the behaviors of variables such as HR, RR, and FiO₂ after initiation of HFNC therapy are related to the success or failure of therapy, no consensus is available regarding the maximum acceptable values, and this lack of agreement makes the use of these variables quite subjective for application in clinical practice.

This study aims at identifying nonphysiological markers (different from RR, FiO₂, SpO₂) associated with the failure of HFNC therapy that could be used during an early stage to identify therapeutic failure and early escalation for ventilatory support. To date, few studies have discussed the nonphysiological risk factors associated

Pediatric Intensive Care Unit, Department of Pediatrics, Hospital Israelita Albert Einstein, Albert Einstein Avenue, 627-701, São Paulo, SP 05651-901, Brazil. Email: milenasn@einstein.br
with failure of HFNC therapy. Variables such as the need to use a nasogastric tube during HFNC use\(^ {17}\), age\(^ {18}\), and equipment model\(^ {19}\) were already studied in attempts to determine an association with severity of respiratory failure; however, none of them has studied the association with HFNC therapy failure. Our hypothesis is that the need to use a nasogastric tube during HFNC use is a marker of HFNC therapy failure.

**Methods**

**Study type and site.** A retrospective observational study was carried out through analysis of the medical records of children who met the inclusion criteria after approval by Albert Einstein Hospital's research ethics committee and is registered under CAAE number 77279317.4.0000.0071; the informed consent term was waived by the ethics and research committee of the Hospital Israelita Albert Einstein. All research was performed in accordance with relevant guidelines/regulations. This study received no funding.

**Inclusion criteria and dependent variables.** The sample included children younger than 2 years of age with primary diagnosis of bronchiolitis and who received an HFNC as the first-choice treatment for respiratory failure. All patients were admitted to the pediatric intensive care unit of a private hospital in the city of São Paulo from January 2016 to June 2017. A patient's medical record number was used, each patient had an extensive revision of the medical record and data were collected by a physical therapist.

The analyzed variables included age, sex, weight on admission, PIM2, M-WCAS score, need for sedation, the need to use a nasogastric tube during HFNC use, equipment model, duration of HFNC use, time between hospital admission and start of HFNC, total oxygen time, and length of hospital stay. The M-WCAS is a score comprising five topics: SpO\(_2\), inspiratory breath sounds, expiratory wheezing, accessory muscles and cerebral functions\(^ {20}\). The score was measured immediately before the HFNC installation. The protocol of nasogastric tube use indication is based on clinical evaluation by the physician according to the severity of respiratory failure. This evaluation follows subjective criteria of the physician and does not include a specific value of RR or SpO\(_2\). The first attempt is always for the oral feeding. Infants are often evaluated with respect to oral ingestion, and those who did not maintain adequate ingestion have a medical indication for the use of a nasogastric tube.

**Primary and secondary outcomes.** The primary outcome was considered to be failure of HFNC therapy, and the secondary outcomes were time of oxygen use and length of hospital stay.

**Criteria for HFNC therapy failure.** As in our institution, criteria for HFNC therapy failure were not yet established (one of the reasons for the study), and failure of HFNC therapy was based on evaluation by the assisting team, being defined as the need for NIV (defined as using BIPAP or CPAP) or IMV.

**High-flow equipment.** One of the two systems available in the pediatric ICU was used to perform HFNC therapy: the Optiflow system (Fisher & Paykel Healthcare, Auckland, New Zealand) or the Precision Flow system (Vapotherm, New Hampshire, USA). The Optiflow system was used in association with the babyBay 1150-S (Fanem Ltda, Guarulhos—Brazil). Four sizes of Optiflow junior nasal cannulas (Fisher and Paykel Healthcare) were used as appropriate for each patient: OPT312 premature, OPT314 neonatal, OPT316 infant, and OPT 318 pediatric. The Precision Flow system was used with cannulas of 5 different sizes: neonate, infant, small pediatric, and pediatric. The protocol was based on a flow rate of 2.0 L kg\(^{-1}\) min\(^{-1}\) for patients up to 10 kg, and for patients greater than 10 kg, flow rates of 2.0 L kg\(^{-1}\) min\(^{-1}\) to the tenth kilogram and 0.5 L kg\(^{-1}\) min\(^{-1}\) after the eleventh kilogram were used.

**Statistical analysis.** Categorical variables are expressed as absolute frequencies and percentages. Numerical variables were assessed for their distributions using boxplots and are expressed as medians and quartiles due to the presence of asymmetric distributions and outliers. The results are presented for the overall data and according to the failure or success of HFNC therapy.

To compare the profiles of patients with and without the need for use of a nasogastric tube during HFNC, we also investigated the associations between age, time between hospital admission and start of HFNC, equipment model and the need for a nasogastric tube during HFNC therapy with failure to use the HFNC through logistic regression models. The results were presented for odds ratios, 95% confidence intervals for odds ratios (95% CI) and p-values. Associations of failure occurrence with factors were investigated through logistic models. The analyses were performed with SPSS software (SPSS version 13.0, SPSS, Chicago, Illinois) considering a significance level of 5%.

**Results**

Of the 1749 children admitted during the study period, 363 (20.8%) received a primary diagnosis of bronchiolitis. For these 363 patients, the first choice respiratory support was room air for 75 (20.7%), conventional oxygen therapy for 192 (52.9%), the need to use NIV for 11 (3.0%), the need to use IMV for 2 (0.5%), and HFNC therapy for 83 (22.9%). HFNC therapy failure occurred in 18 patients (21.7%), 17 (20.5%) required NIV, 5 (6.0%) required IMV, and 4 required both IMV and NIV.

Table 1 presents the main demographic characteristics and main clinical interventions of the patients overall, according to HFNC success or failure. No differences in demographic characteristics were observed between the groups; however, the patients with failure used more midazolam (p < 0.001) and fentanyl (p < 0.002). In the
analysis of the total duration of HFNC therapy, the patients with failure used the HFNC for less time compared with the success group: 12.8 h versus 56.8 h (p < 0.001).

In the comparison of groups that used and did not use the nasogastric tube during HFNC use, we observed evidence of differences in terms of age (p = 0.031) and patients’ weight at admission (p = 0.003), in which the group that did not use the nasogastric tube had higher mean age and weight than the group with the use of the nasogastric tube (Table 2). The association of the occurrence of failure of the HFNC with the use of the nasogastric tube was investigated using a logistic model controlling for age. This adjustment was conducted to control the association observed between age and nasogastric tube use. Measures of age and weight were strongly correlated (r = 0.784; p < 0.001), and therefore, these two measures were not included in the same model. We chose age for inclusion in the model.

Table 3 shows the results of univariate and multivariate logistic regression model approaches by evaluating the associations between failure and factors of interest. The results of logistic models showed that for patients requiring a nasogastric tube during HFNC use, the chances of failure were more likely than for patients with oral nutrition (OR = 8.17; 95% CI 2.30–28.99; p = 0.001).

The HFNC failure was not associated with the device used, time between hospital admission and HFNC installation (OR = 1.01; 95% CI 0.98–1.03; p = 0.731), or age (OR = 0.91; 95% CI 0.77–1.08; p = 0.290). A total of 10 (18.8%) patients used the Optiflow system, and 8 (26.6%) individuals used the Precision Flow system (OR = 1.56; 95% CI 0.54–4.52; p = 0.41).

Among the late outcomes evaluated, the patients with therapy failure had longer total durations of O₂ use (p < 0.001) (Fig. 1) and longer hospital stays (p < 0.001) (Fig. 2).

| Variables                          | Total (n = 83) | Success (n = 65) | Failure (n = 18) | p-value |
|------------------------------------|---------------|-----------------|-----------------|---------|
| Age (months)                       | 2.00 [1.00; 6.00] | 3.00 [1.00; 6.00] | 2.00 [1.25; 3.00] | .55§    |
| Sex                                |               |                 |                 |         |
| Male                               | 46 (55.4)     | 39 (60.0)       | 7 (38.9)        | .18*    |
| Female                             | 37 (44.6)     | 26 (40.0)       | 11 (61.1)       |         |
| Weight at admission (kg)           | 5.70          | 5.80            | 4.95            | .11†    |
|                                   | [4.50; 7.55]  | [4.50; 7.80]    | [4.50; 5.60]    |         |
| PIM 2 score—severity (0–100%)      | 0.16          | 0.16            | 0.16            | .73†    |
|                                   | [0.16; 0.20]  | [0.16; 0.20]    | [0.16; 0.20]    |         |
| M-WCAS score                      | 4.00          | 4.00            | 4.00            | .50*    |
|                                   | [3.00; 5.00]  | [3.00; 5.00]    | [3.00; 5.00]    |         |
| Nasogastric tube during HFNC use   | 33 (39.8%)    | 19 (29.2%)      | 14 (77.8%)      | <.001*  |
| Equipment model                    |               |                 |                 | .41†    |
| Optiflow (Fisher & Paykel)         | 53 (63.9%)    | 43 (66.2%)      | 10 (55.6%)      |         |
| Precision flow (Vapotherm)         | 30 (36.1%)    | 22 (33.8%)      | 8 (44.4%)       |         |
| Duration of HFNC use (hours)       | 46.00 [25.87; 70.50] | 56.75 [40.00; 74.67] | 12.75 [8.87; 23.69] | <.001†  |
| Use of midazolam                   | 5 (6.0)       | 0 (0.0)         | 5 (27.8)        | <.001†  |
| Use of fentanyl                    | 4 (4.8)       | 0 (0.0)         | 4 (22.2)        | <.002*  |

Table 1. Demographic characteristics and main clinical interventions of the subjects overall and according to the success or failure of HFNC therapy. Values are presented as the median and interquartile range. p-values for the chi-square test(¶), Fisher’s exact test(†) and Mann–Whitney test(§). PIM 2 pediatric index of mortality, M-WCAS modified Wood’s clinical asthma score, HFNC high-flow nasal cannula.

| Variables                          | Total (n = 83) | Nasogastric tube during HFNC | p-value |
|------------------------------------|---------------|-------------------------------|---------|
| Age (months)                       | 2.00 [1.00; 6.00] | 3.00 [1.00; 6.00]          | 0.03    |
| PIM 2 score—severity (0–100%)      | 0.16 [0.16; 0.20] | 0.16 [0.16; 0.20]         | 0.66    |
| M-WCAS score                      | 4.00 [3.00; 5.00] | 4.00 [3.00; 5.00]         | 0.88    |
| Weight upon admission (kg)         | 5.70 [4.50; 7.60] | 6.50 [4.60; 8.00]         | <.003   |

Table 2. General profile of patients and profile according to the use of nasogastric tube during HFNC. p-values for Mann–Whitney test. Median values and interquartile range. PIM 2 pediatric index of mortality, M-WCAS modified Wood’s clinical asthma score, HFNC high-flow nasal cannula.
Table 3. Results of approach univariate and multivariate logistic models assessing associations between failure and factors of interest. Age was included in the multivariate logistic model to control the observed association between age and use of a nasogastric tube (Table 2). OR: odds ratios, 95% confidence intervals for odds ratios (95% CI) and p-value. HFNC: high-flow nasal cannula.

| Variables                                      | Success failure (n = 65) | Failure (n = 18) | Univariate logistic model | Multivariate logistic model |
|------------------------------------------------|--------------------------|-----------------|---------------------------|-----------------------------|
| Nasogastric tube during HFNC use               |                          |                 |                           |                             |
| No                                             | 46 (70.8%)               | 4 (22.2%)       | 1.0                       | 1.00                        |
| Yes                                            | 19 (29.2%)               | 14 (77.8%)      | 8.47 (2.47; 29.08)        | 8.17 (2.30; 28.99)          |
| Equipment model                                 |                          |                 |                           |                             |
| Optiflow (Fisher & Paykel)                      | 43 (66.2%)               | 10 (55.6%)      | 1.00                      |                             |
| Precision Flow (Vapotherm)                      | 22 (33.8%)               | 8 (44.4%)       | 1.56 (0.54; 4.52)         |                             |
| Time between hospital admission and start of HFNC (hours) |                 |                 |                           |                             |
| Median (Q1; Q3)                                | 6.5 (3.5; 18.8)          | 9.7 (3.9; 20.0) | 1.01 (0.98; 1.03)         | 0.29 (0.82; 1.17)           |
| Age (month)                                    |                          |                 |                           |                             |
| Median (Q1; Q3)                                | 3.0 (1.0; 6.0)           | 2.0 (1.0; 3.0)  | 0.91 (0.77; 1.08)         | 0.98 (0.82; 1.17)           |

Figure 1. Difference in the total duration of oxygen use between the HFNC therapy success and failure groups. Values are presented as the median (horizontal line), 25–75% interquartile range (box) and upper and lower nonoutlier limits (vertical line). p-values are for the Mann–Whitney test.

Figure 2. Difference in the total length of hospital stays between the HFNC therapy success and failure groups. Values are presented as the median (horizontal line), 25–75% interquartile range (boxplot) and upper and lower nonoutlier limits (vertical line). p-values are for the Mann–Whitney test.
Discussion
Our study sought to determine risk factors associated with failure of HFNC therapy and found that the need to use the nasogastric tube during HFNC use was an important clinical marker for HFNC therapy failure.

Recently, some studies have initiated a discussion about whether to use oral nutrition in infants with bronchiolitis using HFNC, but none of them associated the need to use a nasogastric tube and HFNC therapy failure17,21,22.

In our study, the infants requiring a nasogastric tube during HFNC for feeding had higher risk of HFNC therapy failure. Our protocol of nasogastric tube use indication is based on clinical evaluation by the physician according to the severity of respiratory failure. The use of the nasogastric tube was indicated when the oral ingestion was sufficient and/or risk of coughing and bronchoaspiration were determined through the physician assessment.

Sochet et al. reported that oral nutrition in infants with bronchiolitis was well tolerated and that the nasogastric tube was required for infants with higher RR17, and other studies have shown the difficulty with feeding and changes in swallowing that can occur among infants with bronchiolitis, showing that interference of respiratory discomfort can affect the efficacy of suction and the swallowing process23,24. Therefore, the need for a nasogastric tube may be a marker of the severity of respiratory distress.

One possible confounding factor could be the effect of the patients’ age and the need for a nasogastric tube. In our study, there was an association between patient age and weight at admission with the need for a nasogastric tube, but after the adjustment of multivariate analysis of the age of patients, there was no influence of this variable upon the use of the nasogastric tube as a predictor of HFNC failure; other authors found similar results to our study15,18. On the other hand, Suessman et al. observed a higher risk of intubation in breastfed babies younger than 2–3 months of age19.

There was no difference in the percentage of HFNC failure when two HFNC delivery systems were compared. Weiler et al. used the same two devices adopted in our study. The result was similar, and failure of therapy showed no association with the type of equipment used19.

In our study, the duration of HFNC use by the patients with HFNC therapy failure was lower than that in the patients for whom therapy was successful (12.8 h vs. 56.8 h). The same trend was described by Betters et al.13 (5.5 h vs. 28.0 h). Other authors mention that the durations of HFNC use among patients with therapy failure were 7 h and 14 h, which are similar to our results15,18. Studies related to NIV failure have shown that patients who did not have short-term results (1 to 2 h) were at increased risk of NIV failure25,26 and that the delay in interrupting NIV may have been associated with increased mortality27,28.

The importance of finding a marker for HFNC failure is that this can result in earlier detection, avoiding muscle fatigue and deterioration of the respiratory system.

Regarding the late outcomes, our study observed a shorter duration of oxygen use and a shorter hospital stay in the patients with successful HFNC therapy. Er et al.14 also found a difference in the lengths of hospital stays between patients who responded and did not respond to HFNC therapy. In contrast, with these findings, studies comparing HFNC therapy with conventional oxygen therapy found no difference in the lengths of hospital stays or the durations of oxygen use18,29, suggesting that the impact on these outcomes may be associated with the need for more advanced support, such as CPAP, bilevel positive airway pressure (BIPAP) or IMV.

Our study has the implicit limitations of a retrospective study. Another limitation of this study is the small number of patients with HFNC failure during the study period. Although 83 patients were included, only 18 had HFNC failure, which limited the power of the analyses. To date, studies evaluating risk factors for HFNC therapy failure have shown similar profiles to that found in our study. A total of 18 infants were observed in the sample of the failed group, 14 infants in Betters’ study14, and 8 in Mayfield’s study29. Overall, the percentage of HFNC failure among infants with bronchiolitis is low, and this result directly reflects sample size.

In conclusion, the need to use a nasogastric tube during HFNC use was associated with HFNC therapy failure, and this association can be considered as a marker of severity in children with bronchiolitis and serves as an alert parameter for early staging for other ventilatory support.

Received: 23 January 2020; Accepted: 31 August 2020
Published online: 28 September 2020

References
1. Gaillard, D. et al. Airway epithelial damage and inflammation in children with recurrent bronchitis. Am. J. Respir. Crit. Care Med. 150, 810–817 (1994).
2. Ralston, S. L. et al. Clinical practice guideline: The diagnosis, management, and prevention of bronchiolitis. Pediatrics 134, e1474–e1502 (2014).
3. Cunningham, S. Respiratory support in bronchiolitis: Trial evidence. Am. J. Perinatol. 35, 553–556 (2018).
4. Bressan, S. et al. High-flow nasal cannula oxygen for bronchiolitis in a pediatric ward: A pilot study. Eur. J. Pediatr. 172, 1649–1656 (2013).
5. Milesi, C. et al. Is treatment with a high flow nasal cannula effective in acute viral bronchiolitis? A physiologic study. Intensive Care Med. 39, 1088–1094 (2013).
6. Kubicka, Z. J., Limauro, J. & Darnall, R. A. Heated, humidified high-flow nasal cannula therapy: Yet another way to deliver continuous positive airway pressure?. Pediatrics 121, 82–88 (2008).
7. Lenglet, H. et al. Humidified high flow oxygen during respiratory failure in the emergency department: Feasibility and efficacy. Respir. Care. 57, 1873–1878 (2012).
8. Wing, R., James, C., Maranda, L. S. & Armsby, C. C. Use of high-flow nasal cannula support in the emergency department reduces the need for intubation in pediatric acute respiratory insufficiency. Pediatr. Emerg. Care. 28, 1117–1123 (2012).
9. Milesi, C. et al. High-flow nasal cannulae: Recommendations for daily practice in pediatrics. Ann. Intensive Care. 4, 29 (2014).
10. McKiernan, C., Chua, L. C., Visintainer, P. F. & Allen, H. High flow nasal cannulae therapy in infants with bronchiolitis. J. Pediatr. 156, 634–638 (2010).
11. Schubler, A. et al. Reduced intubation rates for infants after introduction of high-flow nasal prong oxygen delivery. *Intensive Care Med.* 37, 847–852 (2011).
12. Guillot, C. et al. First-line treatment using high-flow nasal cannula for children with severe bronchiolitis: Applicability and risk factors for failure. *Arch. Pediatr.* 25, 213–218 (2018).
13. Betters, K. A., Gillespie, S. E., Miller, J., Kotzbauer, D. & Hebbar, K. B. High flow nasal cannula use outside of the ICU; factors associated with failure. *Pediatr. Pulmonol.* 52, 806–812 (2017).
14. Er, A. et al. Early predictors of unresponsiveness to high-flow nasal cannula therapy in a pediatric emergency department. *Pediatr. Pulmonol.* 53, 809–815 (2018).
15. Abboud, P.A., Roth, P.J., Skiles, C.L., Stolfi, A. & Rowin, M.E. Predictors of failure in infants with viral bronchiolitis treated with high-flow, high-humidity nasal cannula therapy. *Pediatr. Crit. Care Med.* 13, e343–e349.23 (2012).
16. Franklin, D. A randomized trial of high-flow oxygen therapy in infants with bronchiolitis. *N. Engl. J. Med.* 378, 1121–1131 (2018).
17. Sochet, A. A., McGee, J. A. & Waezeh, T. Oral nutrition in children with bronchiolitis on high-flow nasal cannula is well tolerated. *Hosp. Pediatr.* 7, 249–255 (2017).
18. Suessman A, Gray LL, Cavenough S, et al. Clinical factors associated with intubation in the high flow nasal cannula era. *Am. J. Emerg. Med.* (2019)
19. Weiler, T. et al. The relationship between high flow nasal cannula flow rate and effort of breathing in children. *J. Pediatr.* 189, 66–71 (2017).
20. Duarte-Dorado, D. M. et al. Validation of a scale to assess the severity of bronchiolitis in a population of hospitalized infants. *J. Asthma* 50(10), 1056–1061 (2013).
21. Lerose, M.K., Good, R.J., Skillman, H.E. & Czaja, A.S. Enteral nutrition practices in critically ill children requiring noninvasive positive pressure ventilation. *Pediatr. Crit. Care Med.* 18, 1093–1098 (2017).
22. Shadman, K. A. et al. Feeding during high-flow nasal cannula for bronchiolitis: Associations with time to discharge. *J. Hosp. Med.* 14, e43–e48 (2019).
23. Pinnington, L. L., Smith, C. M., Ellis, R. E. & Morton, R. E. Feeding efficiency and respiratory integration in infants with acute viral bronchiolitis. *J. Pediatr.* 137, 523–526 (2000).
24. Valla, F. V. et al. Nutritional management of young infants presenting with acute bronchiolitis in Belgium, France and Switzerland: Survey of current practices and documentary search of national guidelines worldwide. *Eur. J. Pediatr.* 178(3), 331–340 (2019).
25. Dohna-Schwake, R. C. et al. Non-invasive ventilation on a pediatric intensive care unit: Feasibility, efficacy, and predictors of success. *Pediatr. Pulmonol.* 46, 1114–1120 (2011).
26. Essouri, S., Chevret, L., Durand, P., et al. Noninvasive positive pressure ventilation: five years of experience in a pediatric intensive care unit. *Pediatr. Crit. Care Med.* 7(4), 329–34 (2006).
27. Esteban, A. et al. Noninvasive positive-pressure ventilation for respiratory failure after extubation. *N. Engl. J. Med.* 350, 2452–2460 (2006).
28. Esteban, A. et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: A 28-day international study. *JAMA* 287, 345–355 (2002).
29. Kepreotes, E. et al. High-flow warm humidified oxygen versus standard low-flow nasal cannula oxygen for moderate bronchiolitis (HFWHO RCT): An open, phase 4, randomised controlled trial. *Lancet* 89, 930–939 (2017).
30. Mayfield, S., Bogossian, F., O’Malley, L. & Schibler, A. High-flow nasal cannula oxygen therapy for infants with bronchiolitis: Pilot study. *J. Paediatr. Child Health.* 50, 373–378 (2014).

**Author contributions**
M.N. made substantial contributions to conception and design, acquisition of data, analysis and interpretation of data, been involved in drafting the manuscript and revising it critically for important intellectual content; D.E.R.Q. and G.C.Z.O. made substantial contributions to conception and design and acquisition of data, analysis and interpretation of data; C.M.R. made substantial contributions to conception and design and acquisition of data; C.P. was involved in drafting the manuscript and revising it critically for important intellectual content; C.C.P. been involved in drafting the manuscript given final approval of the version to be published and revising it critically for important intellectual content; C.M.R. been involved in drafting the manuscript given final approval of the version to be published and revising it critically for important intellectual content.

**Funding**
No funding sources were used for the present study.

**Competing interests**
The authors declare no competing interests.

**Additional information**

**Correspondence**
 Requests for materials should be addressed to M.N.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020